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Abstract
Background and Aim: Hyponatremia is common in patients with chronic kidney disease and is associated with increased
mortality in hemodialysis patients. However, few studies have addressed this issue in peritoneal dialysis (PD) patients.
Methods: This prospective observational study included a total of 441 incident patients who started PD between January
2000 and December 2005. Using time-averaged serum sodium (TA-Na) levels, we aimed to investigate whether
hyponatremia can predict mortality in these patients.
Results: Among the baseline parameters, serum sodium level was positively associated with serum albumin (b= 0.145;
p= 0.003) and residual renal function (RRF) (b= 0.130; p= 0.018) and inversely associated with PD ultrafiltration (b=20.114;
p= 0.024) in a multivariable linear regression analysis. During a median follow-up of 34.8 months, 149 deaths were recorded.
All-cause death occurred in 81 (55.9%) patients in the lowest tertile compared to 37 (25.0%) and 31 (20.9%) patients in the
middle and highest tertiles, respectively. After adjusting for multiple potentially confounding covariates, increased TA-Na
level was associated with a significantly decreased risk of all-cause (HR per 1 mEq/L increase, 0.79; 95% CI, 0.73–0.86; p,
0.001) and infection-related (HR per 1 mEq/L increase, 0.77; 95% CI, 0.70–0.85; p,0.001) deaths.
Conclusions: This study showed that hyponatremia is an independent predictor of mortality in PD patients. Nevertheless,
whether correcting hyponatremia improves patient survival is unknown. Future interventional studies should address this
question more appropriately.
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Introduction
Electrolyte handling is universally impaired in patients with
chronic kidney disease (CKD) because of failing kidney function.
Therefore, these patients are vulnerable to complications caused
by electrolyte imbalance. Although this issue is partly resolved by
dialysis treatment, patients with end-stage renal disease (ESRD)
commonly suffer from electrolyte disturbances [1].
Hyponatremia, usually defined as a serum sodium concentra-
tion ,135 mEq/L, is one of the most common electrolyte
disorders and is believed to be an important risk factor for
mortality in patients with many serious medical conditions
including advanced heart failure or liver cirrhosis [2–5]. In these
conditions, it is generally assumed that hyponatremia reflects the
severity of the underlying disease rather than directly contributing
to mortality. Hyponatremia is also common in CKD patients [1].
Moreover, recent studies have shown that lower serum sodium
concentrations are associated with increased mortality in mainte-
nance hemodialysis (HD) patients and CKD patients prior to
dialysis therapy [6–10]. However, the underlying mechanisms are
complex and still need to be clarified. In addition, it is still
uncertain whether hyponatremia itself can contribute to mortality
or merely represents a surrogate marker for other unknown risk
factors in chronic maintenance dialysis patients.
Although peritoneal dialysis (PD) is an established therapeutic
modality in ESRD, characteristics of dialysis treatment clearly
differ between PD and HD. In particular, serum levels of
electrolytes fluctuate between dialysis sessions in patients receiving
HD due to the intermittent nature of HD treatment, while these
levels remain relatively stable in PD patients. This unique feature
led us to investigate which factors are associated with hyponatre-
mia and its clinical outcomes in patients chronic PD. To date, few
studies have addressed this issue, in particular the relationship
between serum sodium level and risk of death, in PD patients [11–
15]. Therefore, the purpose of this study was to investigate
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whether hyponatremia can predict mortality in a large prospective
cohort of incident patients undergoing PD.
Methods
Ethics statement
The study was carried out in accordance with the Declaration of
Helsinki and approved by the Institutional Review Board of Ilsan
Hospital Clinical Trial Center. We obtained informed written
consent from all participants involved in our study.
Patients
The study population included 549 ESRD patients who started
PD at Yonsei University Severance Hospital or NHIS Ilsan
Hospital between January 2000 and December 2005. Exclusion
criteria were 1) ,18 years of age at initiation of PD, 2) follow-up
duration less than 6 months, 3) prior history of HD or a kidney
transplant before the initiation of PD, 4) recovery of kidney
function, or 5) initiation of PD for other reasons such as acute
renal failure or congestive heart failure. Therefore, this prospective
observational study included a total of 441 incident patients
(Figure 1).
Data collection
Demographic and clinical data were collected at the beginning
of PD including age, gender, body mass index (BMI) calculated as
weight/(height)2, cause of ESRD, and presence of diabetes and
coronary artery disease. Each subject was scored using the
Charlson Comorbidity Index at the start of PD. This index is a
scoring system that includes weight factors for important
concomitant diseases [16,17]. All patients underwent urea kinetic
studies within three months of PD initiation including Kt/V urea,
normalized protein catabolic rate (nPCR), percentage of lean body
mass (%LBM), PD ultrafiltration, and residual glomerular
filtration rate (GFR). Residual GFR was calculated as the average
urea and creatinine clearance from a 24-h urine collection [18].
nPCR was calculated by the methods described by Randerson et
al. [19] and normalized to standard body weight (total body
water/0.58). Total body water was estimated by Watson formula
[20]. The %LBM was determined from creatinine kinetics
according to Keshaviah et al. [21]. Laboratory data obtained at
the time of dialysis adequacy measurement were considered
baseline values and included serum sodium, potassium, and
bicarbonate concentrations, serum albumin, ferritin, and serum C-
reactive protein (CRP) levels. All laboratory parameters were
recorded longitudinally throughout the follow-up period, and were
calculated as an average of the mean of measurements every 3-
month period. Because dialysis adequacy is generally measured
within the first month after starting dialysis therapy and every 6
month thereafter in our centers, time-averaged dialysis adequacy
parameters were determined as an average of the mean of the
measurements in every 6-month period. Serum sodium concen-
tration was measured by an electrode-based method (UniCel
DXC 800; Beckman Coulter, Inc., CA, USA) and was corrected
for serum glucose level (in such a case of serum glucose above a
normal of 100 mg/dL) using the following formula: Corrected
sodium=measured sodium+0.0166(serum glucose2100) [22].
Study outcomes
Study participants were followed until December 31, 2011. The
primary outcome parameters were all-cause, cardiovascular, and
infection-related mortality.
Statistical analysis
All values are expressed as the mean 6 standard deviation or
percentages. Statistical analyses were performed using SPSS for
Windows version 13.0 (SPSS, Inc., Chicago, IL, USA) and the
software packages R version 3.0.2. Data were analyzed using
Student’s t–test and the Chi-square test, and ANOVA was used for
multiple comparisons. The Kolmogorov-Smirnov test was used to
determine the normality of the distribution of parameters. If data
were not normally distributed, they were expressed as the median
and interquartile range (or after log-transformation) and were
compared using the Mann–Whitney test or Kruskal-Wallis test.
Relationships between serum sodium and continuous variables
were assessed using Pearson’s correlation coefficient, and categor-
ical variables were evaluated using Spearman’s R test. Multiple
linear regression analysis was performed to identify the determi-
nants of serum sodium level.
Under conditions of competing risk, Kaplan-Meier analyses and
traditional Cox regression models can produce misleading results,
so corresponding competing risk methods were used [23–25]. The
cumulative incidence of death was compared among 3 groups
based on tertile of time-averaged serum sodium (TA-Na) levels (,
137, 137 to 139, and $139 mEq/L) using the K-sample test
developed by Gray [23]. Data for switch to HD, kidney
transplantation, and loss to follow-up were censored in the
analysis. Patients who died within the first 3 months after
converting to HD or receiving a kidney graft were considered
deaths related to PD. To determine risk factors for mortality,
multivariate Cox regression using methods of Fine and Gray [24]
was performed, and four different models were constructed; Model
1 adjusted for epidemiologic parameters including age, sex, BMI,
and Charlson Comorbidity Index score. Model 2 adjusted for all
parameters in model 1 plus medication use including dose of
furosemide, use of icodextrin, and use of high-glucose dialysate.
Model 3 adjusted for all parameters in model 2 plus dialysis dose
including PD ultrafiltration and total Kt/Vurea. Model 4 adjusted
for all parameters in model 3 plus malnutrition-inflammatory
parameters including serum potassium, serum bicarbonate, serum
albumin, serum ferritin, CRP, residual GFR, nPCR, and %LBM.
The results are expressed as a hazard ratio (HR) and 95%
confidence interval (CI). First-order interaction terms between
covariates were examined for all models, but there was no
evidence of an interaction between those covariates. A p–value less
than 0.05 was considered statistically significant.
Figure 1. Flow chart of participants in the cohort. PD, peritoneal
dialysis; HD, hemodialysis; KT, kidney transplant.
doi:10.1371/journal.pone.0111373.g001
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Table 1. Clinical characteristics of the study subjects stratified by time-averaged serum sodium level.
Time-averaged serum sodium (mEq/L; number of subjects)
Total
(n =441)
,137
(n=145)
137 to ,139
(n=148)
$139
(n =148) p for trend
Age (years) 59.2613.8 60.6613.4 58.3614.2 58.8613.8 0.251
Gender (male) 240 (54.4) 76 (52.4) 79 (53.4) 85 (57.4) 0.388
Body mass
index (kg/m2)
22.966.7 22.462.6 23.567.7 22.663.3 0.846
Presence of
diabetes mellitus
227 (51.5) 73 (50.3) 73 (49.3) 81 (54.7) 0.446
Presence of
coronary artery
disease
70 (15.9) 27 (18.6) 24 (16.2) 19 (12.8) 0.176
Charlson
Comorbidity
Index score
3.061.0 3.261.0 3.061.1 3.060.9 0.065
Laboratory
findings*
Serum
sodium (mEq/L)
137.762.7 134.562.1 138.060.6 140.360.9 ,0.001
Serum
potassium
(mEq/L)
4.160.7 4.260.8 4.160.6 4.160.7 0.274
Serum
bicarbonate
(mEq/L)
25.962.4 25.762.3 26.162.3 26.062.5 0.206
Serum
albumin (g/dL)
3.160.5 2.960.5 3.160.6 3.260.5 ,0.001
Serum
ferritin (ng/mL)
274.3 [52–521] 294.7 [52–509] 258.3 [59–521] 271.2 [56–514] 0.314
C-
reactive protein
(mg/dL)
0.7 [0.01–16.2] 0.8 [0.01–14.2] 0.4 [0.01–6.3] 0.8 [0.01–16.2] 0.623
Residual GFR
(mL/min/1.73m2)*
4.0 [0.2–29.3] 3.9 [0.2–18.9] 4.0 [0.3–29.3] 4.4 [0.3–19.0] 0.004
Daily
ultrafiltration
(mL)*
Peritoneal dialysis 731.66569.3 811.26601.6 751.26563.1 634.16531.4 0.008
Total 1827.66691.4 1847.66706.0 1794.26700.2 1841.46671.3 0.943
Automated
peritoneal dialysis
5 (1.1) 1 (0.7) 2 (1.4) 2 (1.4) 0.594
Icodextrin use
daily
35 (7.9) 25 (17.2) 10 (6.8) 0 (0.0) ,0.001
2.5% and/or
4.25% dialysate
use daily
105 (23.8) 38 (26.2) 41 (27.7) 26 (17.6) 0.081
Total weekly
Kt/V urea*
2.360.8 2.260.7 2.360.9 2.460.8 0.061
nPCR (g/Kg/day)* 0.960.3 0.960.3 0.960.3 1.060.2 0.012
Lean body mass
(% body weight)*
66.4612.4 61.4611.9 66.8613.8 67.4614.2 ,0.001
Anti-hypertensive
medications
ACE inhibitor
or ARB
302 (68.5) 98 (67.6) 104 (70.3) 100 (67.6) 0.995
Alpha and/or beta blocker 217 (49.2) 72 (49.7) 78 (52.7) 67 (45.3) 0.450
Calcium
channel blocker
265 (60.1) 86 (59.3) 91 (61.5) 88 (59.5) 0.981
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Results
Patient characteristics
The mean age of the patients was 59.2 years (range, 22 to 85
years), 54.4% were males, and patients were on PD for a mean
duration of 43.2 months (range, 6 to 142 months). The mean
baseline and TA-Na levels were 138.263.7 mEq/L and
137.762.7 mEq/L (median, 138.1 mEq/L; range, 126.2 to
143.1 mEq/L) respectively. Table 1 details the baseline charac-
teristics of the 441 patients categorized by tertile of TA-Na level.
Serum albumin (p for trend ,0.001), residual GFR (p for
trend= 0.004), nPCR (p for trend= 0.012), and %LBM (p for
trend ,0.001) were higher at higher TA-Na level, whereas PD
ultrafiltration (p for trend= 0.008) and use of icodextrin (p for
trend ,0.001) were lower at higher TA-Na level. However, we
observed no significant differences in the types of antihypertensive
agents, dosage of furosemide used, or use of high-glucose dialysate
according to TA-Na level.
Factors associated with baseline serum sodium
Correlation analyses were performed to identify factors associ-
ated with baseline serum sodium level (Table 2). There was no
correlation between age, gender, BMI, Charlson Comorbidity
Index score, serum potassium, serum CRP, total Kt/V urea,
nPCR and serum sodium. In contrast, baseline serum sodium level
positively correlated with serum albumin (r=0.177; p,0.001),
residual GFR (r=0.211; p,0.001), and %LBM (r=0.109;
p=0.022), whereas it inversely correlated with serum ferritin level
(r=20.133; p=0.005) and PD ultrafiltration (r=20.169; p,
0.001). A multivariate linear regression analysis that was adjusted
for these factors revealed that serum albumin (b=0.145;
p=0.003), residual GFR (b=0.130; p=0.018), and PD ultrafil-
tration (b=20.114; p=0.024) were independently associated with
baseline serum sodium.
Hyponatremia as a predictor of mortality
During follow-up, 149 deaths were recorded, and the median
survival period was 34.8 months (range, 6.0 to 142.2 months).
Infection (37.6%) was the most common cause of death in this
study, followed by cardiovascular disease (36.2%). All-cause death
occurred in 81 (55.9%) patients in the lowest tertile compared with
37 (25.0%) and 31 (20.9%) patients in the middle and highest
tertiles (p,0.001), respectively. Similar findings were observed for
cardiovascular and infection-related deaths (data not shown).
Higher TA-Na was associated with lower mortality (Table 3).
Even after adjusting for various parameters, the association
between the two was significant and consistent. Using serum
TA-Na as a continuous variable, the HR for all-cause mortality
was 0.79 for every 1 mEq/L increase in TA-Na (95% CI, 0.73–
0.86; p,0.001), indicating that higher TA-Na was significantly
associated with decreased risk of mortality. Moreover, the
increased mortality risk associated with lower TA-Na was similar
for infection-related (HR, 0.77 per 1 mEq/L higher TA-Na; 95%
CI, 0.70–0.85; p,0.001) death. In addition, patients with TA-
Na,137 mEq/L conferred a 3.35- and 3.18-fold increased risk of
all-cause and infection-related mortality, respectively, compared
with patients with TA-Na$139 mEq/L. However, the risk for
cardiovascular death was not associated with TA-NA levels. The
cumulative incidence of death was significantly lower in patients
with higher TA-Na level compared to patients with a TA-Na level
,137 mEq/L (Figure 2).
Discussion
In this study, we sought to delineate the relationship between
serum sodium level and mortality in our ESRD cohort of patients
with PD. We showed that serum sodium level exhibited a
significant positive association with serum albumin and residual
renal function (RRF), while it inversely correlated with PD
ultrafiltration. In addition, low TA-Na level independently
predicted all-cause mortality, suggesting that hyponatremia is a
potential predictor of adverse outcomes in these patients.
Serum sodium concentration in humans is tightly regulated and
the presence of hypotonic hyponatremia implies that the
extracellular fluid compartment contains water in excess of
sodium. Interestingly, the kidneys’ ability to dilute urine, that is
to elaborate urine with minimal osmolality, is generally preserved
even in advanced CKD. However, its ability to concentrate is,
indeed, severely limited in these patients [26]. Furthermore, in
ESRD patients, water and sodium removal are almost exclusively
determined by dialysis procedure, particularly when accompanied
by complete loss of RRF. Therefore, dialysis-dependent patients
are vulnerable to develop dysnatremia. However, the clinical
impact of hyponatremia in these patients has been inadequately
studied.
Table 1. Cont.
Time-averaged serum sodium (mEq/L; number of subjects)
Total
(n =441)
,137
(n=145)
137 to ,139
(n=148)
$139
(n =148) p for trend
Thiazide
or thiazide-like
diuretics
48 (10.9) 19 (13.1) 13 (8.8) 16 (10.8) 0.534
Lasix or
other loop
diuretics
200 (45.4) 64 (44.1) 71 (48.0) 65 (43.9) 0.966
Dose of
furosemide
(mg/day)
46.8661.6 48.7663.5 52.4666.1 39.4654.4 0.192
Values for categorical variables are given as number (percentage); values for continuous variables are given as mean 6 standard deviation or median [interquartile
range].
*Laboratory and dialysis-specific parameters are given as time-averaged values. GFR, glomerular filtration rate; nPCR, normalized protein catabolic rate; ACE, angiotensin
converting enzyme; ARB, angiotensin receptor blocker.
doi:10.1371/journal.pone.0111373.t001
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In our study, hyponatremia (defined as ,135 mEq/L) was
present in 58 patients (13.2%) at the initiation of PD. However,
previous studies of PD patients have used a more strict definition
of hyponatremia (defined as #130 mEq/L on 2 consecutive
measurements) [13–15]. When we use this definition, 11 patients
(2.5%) presented with hyponatremia at the start of PD. In
addition, 21 patients (4.8%) developed hyponatremia during
follow-up, which was comparable with the 5.2% of patients
reported in a previous study by Zevallos et al. [13] but much lower
than the 14.5% of patients observed in a recent study by
Dimitriadis et al [14]. However, when we defined hyponatremia as
,135 mEq/L, which is the threshold generally accepted in clinical
practice, 115 patients (26.1%) developed hyponatremia during the
follow-up period. These findings suggest that hyponatremia is
common in PD patients, although the incidence may differ
depending on the chosen definition.
The underlying mechanisms for hyponatremia in PD patients
are complex and unclear. In general, as suggested by Edelman et
al. [27], serum sodium concentration is determined by rapidly
exchangeable body sodium, potassium, and total body water.
Thus, hypotonic hyponatremia typically develops due to decrease
in the fraction of body sodium and potassium over body water.
Such reduction is potentially caused by various combinations of
changes in body cations and water. In particular, the cation
fraction can be often decreased in patients on dialysis because
these patients are prone to fluid overload. In addition to this
mechanism, dialysis-specific conditions should be taken into to
explain hyponatremia in dialysis patients. Of note, therapeutic
modality itself such as diffusive transport, convective transport,
and ultrafiltration can induce the changes of body cations and
water and thus results in altered serum sodium concentrations in
PD patients [28]. Therefore, in patients on PD, alterations in
serum sodium concentrations can occur as a result of the dialytic
and nondialytic changes in the mass balance of body sodium, body
potassium, and body water.
In addition, osmotic shift of water from the intracellular into the
extracellular compartment and intracellular entry of sodium are
putative mechanisms of PD-associated hyponatremia in certain
clinical states, including potassium deficit, protein-energy wasting
(PEW) and use of icodextrin solutions as PD dialysate [13,29–31].
However, although there is evidence suggesting that entry of
extracellular sodium into the cells causes hyponatremia in various
settings [13,29–31], hyponatremia is unlikely to occur unless such
a shift is accompanied by imbalances of monovalent cations and
water that decrease the cation fraction as aforementioned.
The most important finding in this study is the strong and
significant association between lower serum sodium concentration
and mortality in PD patients. This association has previously been
shown in maintenance dialysis patients and CKD patients prior to
dialysis therapy [6–10,12,15]. In keeping with these, our robust
finding supports evidence that hyponatremia portends a poor
prognosis in these patients. In multivariate models with rigorous
adjustments, low serum sodium concentration remained an
independent predictor of mortality. In addition, patients with
TA-Na level ,137 mEq/L had adjusted HRs for all-cause, and
infection-related mortality of 3.35 and 3.18, respectively, com-
pared to the reference group with TA-Na level $139 mEq/L,
indicating that higher serum sodium level is associated significantly
with lower mortality risk. Relevant to our finding is a recent
observation in HD patients based on data from the Dialysis
Outcomes and Practice Pattern Study, showing that patients with
mean serum sodium level ,137 mEq/L had a 45% higher risk of
death compared with patients with serum sodium $140 mEq/L
[7].
The underlying mechanisms for increased mortality in ad-
vanced CKD patients with lower serum sodium level are also
unclear. In severely ill patients without CKD, vasopressin is
secreted in response to neurohormonal activation. Whether
vasopressin contributes to the development of hyponatremia in
patients with CKD is largely unknown. Possibly, vasopressin could
explain the association between hyponatremia and mortality in
this population if it acts in the same manner as in non-CKD
patients with serious underlying conditions [32]. In addition,
hyponatremia is related to other adverse features. In particular,
reduced RRF may limit free water clearance, resulting in
hyponatremia. Interestingly, RRF was identified as a significant
factor associated with baseline serum sodium in this study; higher
residual GFR was independently associated with a higher serum
Figure 2. The Cumulative incidence of all-cause (A), cardiovascular (B), and infection-related (C) mortality based on the level of
time-averaged serum sodium (TA-Na).
doi:10.1371/journal.pone.0111373.g002
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sodium concentration. This finding suggests that residual kidney
function even in the advanced stage can contribute to sodium
handling and prevent hyponatremia by excreting relatively more
water than sodium. Conversely, loss of RRF in the end may result
in inability to control excess water, leading to hyponatremia.
Furthermore, PEW status may affect sodium level by depleting
intracellular potassium and solutes [13,29]. In the present study,
there were significant associations between serum sodium level and
some nutritional markers such as serum albumin and %LBM. If
this is the case, low sodium level can represent underlying
unfavorable conditions. Finally, inflammatory response has
recently been suggested as a cause of hyponatremia [33–35].
Among many inflammatory markers, interleukin-6 is reported to
induce central vasopressin secretion [35]. Of note, loss of RRF,
PEW, and inflammation are established predictors of mortality in
patients on dialysis [36–38], and all of the aforementioned
mechanisms together may account for the association between
hyponatremia and mortality in these patients.
There are several limitations to the present study. This was an
observational study with a relatively small sample size. Hence,
causality of our findings needs further confirmation. In particular,
there has been much concern about whether hyponatremia
directly causes death or is merely a marker of disease severity.
Furthermore, it is unknown whether correcting hyponatremia can
improve clinical outcomes in CKD patients. A detailed discussion
about these issues is beyond our scope. However, it is likely that
hyponatremia can occur in severe underlying conditions and may
itself further increase the risk of adverse outcomes. Lack of
information to further explain hyponatremia is another drawback.
Because this was an observational study, we could not collect data
describing the amount of sodium removed by PD or the amount
being ingested in the diet. Other data representing overall volume
status such as body weight changes, dietary water intake, and a
bioelectrical impedance analysis were not available for analysis.
Despite these limitations, this study showed that low TA-Na level
independently predicted all-cause and infection-related mortality,
even after extensive adjusting for demographic, clinical, laborato-
ry, and dialysis-specific covariates. Our robust findings suggest that
hyponatremia portends a poor prognosis, and thus physicians
should be more meticulous in clinical practice with respect to
correcting both this electrolyte imbalance and underlying disease.
Conclusion
This study showed that a low serum sodium concentration was
an independent predictor of mortality in PD patients. The
relationship between low serum sodium level and adverse
outcomes may be attributed to loss of RRF and underlying
conditions such as PEW. Whether correcting hyponatremia
improves patient survival requires further investigations.
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